Leerink Partnrs Issues Negative Outlook for GPCR Earnings

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) – Leerink Partnrs dropped their Q4 2025 EPS estimates for Structure Therapeutics in a report released on Thursday, August 7th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings per share of $2.51 for the quarter, down from their prior forecast of $2.58. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share.

A number of other research firms have also commented on GPCR. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a report on Monday, June 23rd. Guggenheim decreased their price target on shares of Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating for the company in a report on Thursday. HC Wainwright decreased their price target on shares of Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating for the company in a report on Thursday. JMP Securities decreased their price target on shares of Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating for the company in a report on Thursday. Finally, Citigroup began coverage on shares of Structure Therapeutics in a report on Friday, May 2nd. They issued a “buy” rating and a $60.00 price target for the company. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics currently has an average rating of “Buy” and a consensus price target of $75.71.

Structure Therapeutics Stock Performance

GPCR opened at $16.31 on Friday. The company has a fifty day moving average price of $19.78 and a two-hundred day moving average price of $21.81. Structure Therapeutics has a 52 week low of $13.22 and a 52 week high of $45.37. The firm has a market capitalization of $935.22 million, a PE ratio of -15.53 and a beta of -1.89.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08).

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Mariner LLC bought a new stake in Structure Therapeutics in the 4th quarter valued at $665,000. Invesco Ltd. lifted its position in Structure Therapeutics by 4.1% in the 4th quarter. Invesco Ltd. now owns 371,767 shares of the company’s stock valued at $10,082,000 after acquiring an additional 14,559 shares in the last quarter. Barclays PLC lifted its position in Structure Therapeutics by 42.6% in the 4th quarter. Barclays PLC now owns 115,671 shares of the company’s stock valued at $3,138,000 after acquiring an additional 34,533 shares in the last quarter. GAMMA Investing LLC lifted its position in Structure Therapeutics by 663.8% in the 1st quarter. GAMMA Investing LLC now owns 8,776 shares of the company’s stock valued at $152,000 after acquiring an additional 7,627 shares in the last quarter. Finally, Foresite Capital Management VI LLC bought a new stake in Structure Therapeutics in the 4th quarter valued at $11,390,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.